Alzheimer International Society has launched the International United Front Against Alzheimer™ (IUFAA) with the following objectives to:

• Collaborate on the development of prevention and drug treatment therapy for Alzheimer.
• Accelerate on the development of biomarkers and diagnostics.
• Harmonize and speed up the AD drug approval processes between regional and international clinical trial systems.
• Partner with the International Funds Against Alzheimer to raise $1 Billion to fund new concepts and clinical trials of new Alzheimer drugs with proof of safety and efficacy.
• Focus resources to bring newly approved drugs to the market by 2025.
• Support the evidenced-based Dementia care practices.

The International Fund Against Alzheimer’s is funded by a globally diverse group of institutional investors, including foundations, endowments, family offices, financial institutions and pension funds.

The Alzheimer's Drug Development Symposium (ADDS) 2025 will be held in conjunction with the Alzheimer Society International Congress, November 12-14, 2025 in San Francisco.

• The ADDS Symposium brings together leading drug developers and business leaders in the Alzheimer’s community to discuss and exchanges ideas on how to solve the translational challenges, the holy grail of medical research to find a treatment or prevention for Alzheimer’s disease.
• The Symposium will serve as a great network opportunity for biopharmaceutical executives to explore research collaboration, technology licensing and merger & acquisition.
• In addition, the ADDS Symposium presents a panel featuring prominent investment bankers to discuss the state of the industry, challenges and opportunities of direct investment in biopharmaceutical companies that develop therapeutic treatment and prevention of Alzheimer's disease..